Searched for
BIO GENERIC DRUGS
Bio Medica Laboratories shares to debut today. Here's what GMP suggests ahead of listingBio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Bio Medica Laboratories IPO: Check GMP, price band, subscription and other detailsBio Medica Laboratories' initial public offering begins subscription on Thursday. The company plans to raise Rs 52.43 crore through its IPO...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- ET MSME Awards 2025: India's pharma MSMEs face existential choiceNew bio-equivalence rules promise safer drugs but could eliminate pharma manufacturers that make medicines affordable. Is there a middle gr...
- Sajjala Bio to begin clinical trials on diabetes drugIn a statement, the Hyderabad-based company that reported Rs 15 crore of revenue last fiscal year, said it would soon take up clinical stud...
- Torrent Pharma buys US firm Bio-PharmTorrent Pharma said it plans further investments to expand the BPI facilities, including its research and development (R&D) capabilities, a...
- PM Narendra Modi's proposal over generic drugs isn't a new oneModi’s latest salvo has resurrected the ghost for the Rs 17,000 crore Indian pharma market dominated by branded generics.
- Sharon Bio-Medicine gets USFDA nod for API plant in TalojaThe inspection was conducted during June 29, 2015 to July 7, 2015 at the Taloja plant, it added.
- Germany suspends marketing of 54 drugs tested by GVK BiosciencesGermany's drug regulator has suspended the marketing of 54 medicines clinically tested by India's GVK Biosciences in compliance.
- EU bans 700 generic drugs for manipulation of trials by GVK BiosciencesMedicines affected by the sales ban will lose their validity for use in the EU and they should no longer be sold by pharmaceutical companie...
- USFDA issues warning letter to Sharon Bio-medicineThe US regulator has issued a warning letter to Sharon Bio-medicine for failing to pay generic drug user fee by its owner for three years.
- Lupin submits fresh studies for two products suspended by EMALupin said that company has successfully conducted the new bio equivalence (BE) studies for the said products and submitted the report to E...
- GVK Bio manipulated clinical trials of generic drugs: ReportsThe Federal Institute for Medicines and Medical Products, which issues the licences in Germany, confirmed it has been investigating the all...
- Transgene Biotek joins hands with Mauritius-based FII, to delist sharesTransgene Biotek has announced that Stream Value Fund has agreed to join hands on a long-term basis to support its drug discovery activity.
- US health bill to benefit local generic firmsThe US healthcare bill, which has been passed by the US House of Representatives and is awaiting nod from the Senate, holds a lot of promis...
- DRL seeks USFDA help to make cancer drug cloneUS-based biotech firm Celgene, the innovator, has declined to make the drug samples available to DRL for bio-equivalence studies.
- Jubilant gears up for bigger play in generic drugsJubilant Organosys is planning to expand its presence in the generic drugs space. The company plans to file applications to sell 10 off-pat...
- Malaysian firm to sign $ 2 mn deal with AvesthaA leading Malaysian drug and biotechnology firm will sign a USD two million deal with India's Avestha Gengraine Technologies Pvt Ltd to man...
- Pharma cos eyeing US generic drugs spaceAt a time when the US generic drugs market is reeling under price competition, a recent move by the US government to accelerate approvals o...
Load More
